(Q38460247)

English

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

scientific article published on 04 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

M M Mita

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

E Poplin

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

C D Britten

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

W D Tap

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

E H Rubin

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

B B Scott

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

L Berk

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

V M Rivera

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

J W Loewy

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

P Dodion

10

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

F Haluska

11

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

J Sarantopoulos

12

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

A Mita

13

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

A Tolcher

14

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

4 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1104-1111

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

TOR, a central controller of cell growth

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

PI3K-Akt pathway: its functions and alterations in human cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Targeting mTOR signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

The target of rapamycin (TOR) proteins

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

The mTOR pathway: a new target in cancer therapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Therapeutic targets: MTOR and related pathways

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Everolimus: in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Temsirolimus: in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS602

21 January 2018

Identifiers

10.1093/ANNONC/MDS602

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38460247&oldid=1760509124"